risperidone microspheres

Long-acting injectable antipsychotic • Brands: RISPERDAL CONSTA

Last reviewed: 2025-12-30

General information

Class: Long-acting injectable antipsychotic
Common US brands: RISPERDAL CONSTA
Long-acting injectable formulation available.
Therapeutic drug monitoring not routinely recommended.
Last reviewed: 2025-12-30

Dosing & forms

Forms/strengths: —
Frequency: —
Food: —
Typical range: —

Mechanism (brief)

Long-acting injectable risperidone formulation (microspheres) providing sustained dopamine D2 and serotonin 5-HT2A antagonism; used for maintenance treatment when adherence support is prioritized.

Metabolism & Half‑life

Metabolism: CYP2D6
Half‑life: Steady-state range 72–144 h

Therapeutic Drug Monitoring (TDM)

Recommended: No

View labelExact

Long‑acting injectable (LAI)

Risperidone microspheres

Interval: q2wk
Oral overlap: Yes — ~3 weeks due to lag
Site: Deltoid or gluteal

Citations

Label DOI PMCID

Monitoring highlights

Sources

RISPERDAL CONSTA (risperidone) long-acting injection — Prescribing Information — DailyMed (2025)
RISPERDAL (risperidone) prescribing information — DailyMed (2025)
Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic — American Journal of Psychiatry (2003)
The CANMAT and ISBD Guidelines for the Management of Patients With Bipolar Disorder: 2021 Update — Bipolar Disorders (2021)